Drug discovery has always started with sick patients. @DCVCBio-backed @alchemabtx flips that—sequencing the immune systems of people who carry disease-causing mutations but never get sick, then using AI to turn those signals into life-saving drugs. Read more below 🧵

At @DCVCBio, we see a need for a massive rein­vest­ment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies. More on our thinking in 🧵

RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans. More in 🧵

We’re seeing a new wave of gene therapy companies developing exquisitely customized viral vectors + other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. 👇 dcvc.com/news-insights/deep-…

How is Grove Biopharma archi­tecting its way around traditional drug limits? Learn from @DCVCBio principal Dr. Emily Park and managing partner @2kstead 👇 (link in 🧵)

Very exciting progress from Latus Bio! Read more from @DCVCBio Managing Partner @2kstead--link below 👇

This #SynBioBeta2024 fireside chat should be a good one: @DCVC GP @jason_pontin and @DCVCBio-backed @creyonbio co-founder/CEO @chrihart will talk about how today's hottest tools—#AI and #MachineLearning—are driving on-demand gene therapies into the clinic.

Our own @cboshuizen will be going to space with @blueorigin very soon. You can send him your questions via DM!

How it started:

The @AbCelleraBio @LillyPad #COVID19 therapy was developed at world record speed - 3 MONTHS from screen to human trials. This is how they did it:

.@DCVC wildlife spotted in the #backcountry

If you enjoy your #pows we have @DCVC @DCVCBio goggle covers! ⛷🏂🥽